Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

In vivo/ex vivo and in situ assays used in cancer research: a brief review.

Teicher BA.

Toxicol Pathol. 2009 Jan;37(1):114-22. doi: 10.1177/0192623308329473. Epub 2008 Dec 19. Review.

PMID:
19098118
2.

Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts.

Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul M.

Clin Cancer Res. 2001 Mar;7(3):634-40.

3.

Acute in vivo resistance in high-dose therapy.

Teicher BA, Ara G, Keyes SR, Herbst RS, Frei E 3rd.

Clin Cancer Res. 1998 Feb;4(2):483-91.

4.

Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development.

Fiebig HH, Schmid JR, Bieser W, Henss H, Lohr GW.

Eur J Cancer Clin Oncol. 1987 Jul;23(7):937-48.

PMID:
3665999
5.

Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.

Yip KW, Mao X, Au PY, Hedley DW, Chow S, Dalili S, Mocanu JD, Bastianutto C, Schimmer A, Liu FF.

Clin Cancer Res. 2006 Sep 15;12(18):5557-69.

6.

Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells.

Bagley RG, Kurtzberg L, Rouleau C, Yao M, Teicher BA.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1537-46. doi: 10.1007/s00280-011-1658-0. Epub 2011 Apr 28.

PMID:
21526352
7.

Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.

Teicher BA, Holden SA, Eder JP, Brann TW, Jones SM, Frei E 3rd.

Cancer Res. 1989 Nov 1;49(21):5994-8.

8.

Transforming growth factor-beta in in vivo resistance.

Teicher BA, Holden SA, Ara G, Chen G.

Cancer Chemother Pharmacol. 1996;37(6):601-9.

PMID:
8612316
9.

CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.

Redjal N, Chan JA, Segal RA, Kung AL.

Clin Cancer Res. 2006 Nov 15;12(22):6765-71.

10.

[Effect of 5 drugs with different antitumor mechanism on tumor-formation potential of rat hepatocarcinoma cells and mesenchymal stem cells].

Zhou Y, Luo M, Zhang J, Zhang WQ, Zhang JR.

Nan Fang Yi Ke Da Xue Xue Bao. 2007 Mar;27(3):290-2. Chinese.

11.

Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.

Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.

Cancer Res. 2001 Dec 15;61(24):8758-68.

12.

In vitro assays of chemotherapeutic sensitivity.

Carney DN, Winkler CF.

Important Adv Oncol. 1985:78-103. Review.

PMID:
3916747
14.

Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination.

Teicher BA, Holden SA, Eder JP, Herman TS, Antman KH, Frei E 3rd.

Semin Oncol. 1990 Feb;17(1 Suppl 3):18-32.

PMID:
2106164
15.

Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma.

Teicher BA, Holden SA, Ara G, Korbut T, Menon K.

Cancer Chemother Pharmacol. 1996;38(2):169-77.

PMID:
8616908
16.

Evaluating response to antineoplastic drug combinations in tissue culture models.

Reynolds CP, Maurer BJ.

Methods Mol Med. 2005;110:173-83. Review.

PMID:
15901935
17.

Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.

Teicher BA, Holden SA, Ara G, Northey D.

Anticancer Res. 1993 Nov-Dec;13(6A):2101-6.

PMID:
7507654
18.

Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.

Donnelly ET, Kelley M, Rockwell S.

Cancer Chemother Pharmacol. 2004 Jan;53(1):43-50. Epub 2003 Oct 22.

PMID:
14574460
19.

Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.

Kurtzberg LS, Roth SD, Bagley RG, Rouleau C, Yao M, Crawford JL, Krumbholz RD, Schmid SM, Teicher BA.

Cancer Chemother Pharmacol. 2009 Oct;64(5):1029-38. doi: 10.1007/s00280-009-0959-z. Epub 2009 Mar 10.

PMID:
19277662
20.

Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.

Strawn LM, Kabbinavar F, Schwartz DP, Mann E, Shawver LK, Slamon DJ, Cherrington JM.

Clin Cancer Res. 2000 Jul;6(7):2931-40.

Supplemental Content

Support Center